EXINI Diagnostics AB
EXINI and Active Biotech present mutual results at US cancer conference
EXINI Diagnostics AB 16.05.2013 08:50 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Lund, Sweden, 2013-05-16 08:50 CEST (GLOBE NEWSWIRE) -- Lund, Sweden, May 16, 2013, EXINI Diagnostics AB (publ), listed on NASDAQ OMX First North and Active Biotech (NASDAQ OMX NORDIC: ACTI) will present data from an oncology project, the drug candidate tasquinimod for the treatment of prostate cancer combined with BSI - evaluation (Bone Scan Index) at the scientific conference '2013 ASCO (American Society of Clinical Oncology) Annual Meeting' to be held in Chicago (USA) on May 31 - June 4, 2013. The study is co-sponsored by Active Biotech, EXINI and Ipsen. (P5081) An Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod. A.J. Armstrong, et al. The Bone Scan Index (BSI) was prognostic for OS in mCRPC patients enrolled in the Phase II multicenter trial of tasquinimod and treatment with tasquinimod was associated with a decreased BSI progression rate. Prostate cancer spreads to the skeleton and bone scan examination is used to observe this. With EXINI's unique BSI scoring the doctors get a measure of how much the cancer has spread. This has proved to be very important for the prognosis. Many patients live for years with prostate cancer without any symptoms, while others have a much more aggressive course of illness. The study shows that a low BSI score is associated with a better prognosis. Magnus Aurell, CEO, EXINI Diagnostics: 'It is very gratifying that our intense focus on EXINI bone and its BSI value now produces results. ASCO is one of the biggest oncology congresses in the world. An ideal place to spread the message of the prognostic value of the BSI scoring to the pharmaceutical companies and the approved presentation shows that there is a great interest among, urologists / oncologists for our index.' For more detailed information, see www.asco.org or www.activebiotech.com Or contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of radiology images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 500 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser. ________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com News Source: NASDAQ OMX
+++++
Additional features:16.05.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: EXINI Diagnostics AB Sweden Phone: Fax: E-mail: Internet: ISIN: SE0001810284 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden